Mount Sinai Beth Israel Receive Award from the Department of Defense to Study Gulf War Illness with electroCore’s Non-Invasive Vagus Nerve Stimulation Therapy
The Pain & Fatigue Study Center at Mount Sinai Beth Israel in New York has been awarded a United States Army Medical Research grant to conduct a study into the treatment of veterans of the 1990-1991 Gulf War who have Gulf War Illness using electroCore’s non-invasive vagus nerve... - November 17, 2016
Presentation from electroCore Shows That Healthcare Costs for Patients with a Primary Headache Diagnosis Cost Four Times More Than a Healthy Patient Due to Comorbidities
Research presented at the Academy of Managed Care Pharmacy (AMCP) Nexus in early October in Washington, DC, showed that 60 percent of adult patients who were diagnosed with primary headache had one or more comorbidities which raised the average annual cost of their healthcare to over $20,000. This... - October 22, 2016
The Journal Headache Reports That electroCore’s Non-Invasive Vagus Nerve Stimulator is an Effective Bioelectric Medicine for Episodic Cluster Headache
In a multi-centered, sham-controlled study conducted in the United States, episodic cluster headache patients using the gammaCore non-invasive vagus nerve stimulation device (nVNS) had a significant and clinically meaningful benefit within 15 minutes of the treatment of the attack, as compared with... - September 14, 2016
ElectroCore’s Non-Invasive Vagus Nerve Stimulation (nVNS) Demonstrates Efficacy in Preventing Cluster Headache and Menstrual Migraine
The results of two studies, presented at the American Headache Society (AHS) Science Meeting last weekend in San Diego, show that using electroCore’s non-invasive vagus nerve stimulation (nVNS) therapy, gammaCore®, is effective at preventing both cluster headache and menstrual migraine. - June 17, 2016
Seven Presentations on electroCore’s Treatment for Cluster Headache and Migraine Will Feature at American Headache Society Science Meeting
Recent clinical and preclinical results using electroCore’s non-invasive vagus nerve stimulation (nVNS, gammaCore®) therapy in the treatment and prevention of primary headache are the subject of seven presentations at the American Headache Society (AHS) Science Meeting being held at San... - June 08, 2016
electroCore's GammaCore is Both Effective and Cost Effective for the Treatment of Cluster Headache
A paper in the Journal of Headache and Pain reports that non-invasive stimulation of the vagus nerve (nVNS) is a cost effective therapy for cluster headache. These findings were based on reductions in medication use and improvements in quality of life. The publication also notes that further... - May 18, 2016
NICE Provides Positive Guidance on electroCore’s gammaCore Treatment for the Prevention and Acute Treatment of Migraine and Cluster Headache
The UK’s National Institute of Health and Care Excellence (NICE) has published guidance that electroCore’s non-invasive vagus nerve stimulation treatment (gammaCore) for the prevention and acute treatment of migraine and cluster headache is safe and can now be used in the NHS. The... - April 09, 2016
Dr Nader N Youssef Appointed Chief Medical Officer of electroCore
Dr Nader N Youssef has been appointed Chief Medical Officer of electroCore, the US based electroceutical healthcare company. Nader brings more than 15 years of clinical, academic, and industry research experience to electroCore. He was previously Executive Director GI Global Clinical Development... - August 09, 2015
The Journal of Headache and Pain Reports That electroCore’s Non-Invasive Vagus Nerve Stimulation (nVNS) Treatment is Effective in Migraines
-- 65% of the study participants reported pain relief(1) by 2 hours after treatment, with 56% already reporting pain relief by one hour, and 35% were pain free by one hour -- Authors stated that nVNS was safe, well tolerated and effective in many patients and may reduce medication overuse and... - July 17, 2015
Patrick Fabbio Appointed Chief Financial Officer at electroCore
Patrick Fabbio has been appointed Chief Financial Officer of electroCore, the US based electroceutical healthcare company. Pat, who was previously VP Finance for NPS Pharmaceuticals, has more than 20 years of financial leadership experience in both public and private life science and pharmaceutical... - June 06, 2015
Patients Embrace gammaCore - the New Non Pharmacologic Treatment for Migraines
A poster at the International Headache Congress(1), in Valencia, reports on a study which examined patients’ attitude to electroCore’s non-invasive vagus nerve stimulation (nVNS) treatment for migraines. The research by the Headache Centre in Rome(2) asked 60 patients why they started... - May 23, 2015
Presentation at International Headache Congress Shows electroCore’s Chronic Cluster Headache Treatment to be Cost-Effective
· electroCore’s gammaCore non-invasive vagus nerve stimulation (nVNS) therapy improves quality of life when added to standard of care (SOC) · gammaCore is cost-effective compared to other treatment options · gammaCore reduces acute medication usage, resulting in a 30%... - May 20, 2015
ElectroCore’s Non-Invasive Vagus Nerve Stimulation Therapy Shown to be Safe and to Produce No Meaningful Cardiac Adverse Effects
At the 67th American Academy of Neurology meeting in Washington, DC, last week a poster presentation showed that electroCore’s non-invasive vagus nerve stimulation (nVNS) therapy does not cause any meaningful cardiovascular adverse effects in patients with asthma. The poster presentation,... - April 30, 2015
ElectroCore: a Finalist in the 2015 FT ArcelorMittal Boldness in Business Awards Technology Category
At the annual FT ArcelorMittal Boldness in Business awards held in London last week electroCore was one of six finalists in the ‘Technology’ category, in a competition that included over 250 companies, which Open Garden won for its FireChat digital app(1). ElectroCore, a world leader... - April 01, 2015
Clinical Study Published in Neurology Finds That Electrocore’s Non-Invasive Vagus Nerve Stimulation is Effective in Treating Cluster Headaches
An open-label study published in the journal Neurology, reports that electroCore’s non-invasive Vagus Nerve stimulation (nVNS) device, gammaCore, is practical and effective as an acute and preventative treatment in cluster headache. - March 05, 2015
A Review in the European Journal of Neurology Confirms That electroCore’s nVNS is Not Only Safe But Could be Effective Across a Wide Range of Conditions
According to a review in the European Journal of Neurology electroCore's non-invasive vagus nerve stimulation therapy is not only safe but could be effective for a wide range of conditions. - January 30, 2015
electroCore CEO, JP Errico, Emphasizes the Importance of Early Collaboration with Patients Group, Providers, and Payors When Introducing Innovative Technologies
JP Errico, founder and CEO of electroCore, speaking at The FT Global Pharmaceutical and Biotechnology Conference in London last week, emphasized the importance of working with each of the major stakeholders, i.e., patients and their advocates, key opinion-leading physicians, and decision-makers... - November 28, 2014
Trial Reported in Headache and Pain Journal Further Confirms the Effectiveness of electroCore’s Non-Invasive Vagus Nerve Stimulation Treatment for Headache
Preliminary results of an open-label trial carried in the journal of Headache and Pain reported that a single treatment with electroCore’s hand held non-invasive vagus nerve stimulation (nVNS) device gammaCore, completely resolved 44.8% of migraines within 30 minutes, with an additional 11.4%... - October 25, 2014
Randomized Data Presented at International Headache Meeting (EHMTIC)) Shows Gammacore Significantly Reduces Cluster Headache Attack Frequency*
The biannual European Headache and Migraine Trust International Conference (EHMTIC) meeting concluded yesterday in Copenhagen, where more than 900 neurologists and other headache specialists came to hear about the latest advances in managing severe headache conditions, including electroCore’s... - September 25, 2014